TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Clearside Biomedical ( (CLSD) ) has shared an announcement.
Clearside Biomedical, Inc. has successfully regained compliance with Nasdaq’s Minimum Bid Price Requirement as of October 6, 2025. This follows a series of events starting from February 7, 2025, when the company was notified of non-compliance due to its stock price falling below $1.00 for 30 consecutive days. After implementing a reverse stock split and presenting a compliance plan to the Nasdaq Hearings Panel, the company has now met the necessary criteria to maintain its listing, closing the matter.
The most recent analyst rating on (CLSD) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Clearside Biomedical stock, see the CLSD Stock Forecast page.
Spark’s Take on CLSD Stock
According to Spark, TipRanks’ AI Analyst, CLSD is a Neutral.
Clearside Biomedical faces significant financial challenges, with declining revenues and negative equity being the most impactful factors. The technical analysis indicates a bearish trend, and valuation metrics are poor. While recent corporate events provide some positive aspects, the overall outlook remains risky.
To see Spark’s full report on CLSD stock, click here.
More about Clearside Biomedical
Average Trading Volume: 312,104
Technical Sentiment Signal: Sell
Current Market Cap: $22.77M
Learn more about CLSD stock on TipRanks’ Stock Analysis page.